Reference Chart
Peptide Mixing Compatibility Chart
Overview
Mixing peptides in the same vial or injection is common in research settings to reduce injection frequency and simplify protocols. However, not all peptides are compatible — differences in pH optima, isoelectric points, solvent requirements, and chemical reactivity can lead to aggregation, precipitation, degradation, or loss of biological activity when incompatible compounds are combined.
Important caveat: Direct compatibility data from head-to-head stability testing is scarce for most research peptide combinations. The assessments below are derived from physicochemical principles (pH, pI, charge, solvent requirements), published stability data for individual compounds, and widely reported preclinical research protocols. They should not be considered definitive without compound-specific stability testing.
The primary factors governing peptide mixing compatibility:
- pH: Peptides have different optimal pH ranges. Combining a compound stable at pH 4–5 with one requiring pH 7–8 forces a compromise that may degrade one or both
- Isoelectric point (pI): At their pI, peptides have zero net charge and are most prone to aggregation. Mixed solutions may shift pH toward the pI of one component
- Solvent requirements: Some peptides (e.g., Melanotan II) require acetic acid for initial dissolution — this acidic environment may degrade pH-sensitive partners
- Disulfide bonds: Peptides with free cysteines (e.g., IGF-1 LR3) can form unwanted disulfide crosslinks with other cysteine-containing compounds
- Concentration effects: Even compatible peptides at very high combined concentrations may aggregate
Compatibility Principles
The table below summarizes compatibility assessments for commonly researched peptide combinations, based on physicochemical properties and reported research protocols.
| Compound | Compatible With | Use Caution | Avoid Mixing | Notes |
|---|---|---|---|---|
| BPC-157 | TB-500, GHK-Cu, Ipamorelin, CJC-1295 | Selank, Semax, DSIP | Acetic acid-reconstituted peptides at high concentration | Stable in BAC water pH ~5; widely co-administered in rodent models |
| TB-500 | BPC-157, GHK-Cu, Ipamorelin | IGF-1 LR3 (disulfide risk) | Melanotan II (very different pH profile) | Thymosin Beta-4 fragment; stable in near-neutral to slightly acidic conditions |
| GHK-Cu | BPC-157, TB-500 | High-concentration GH peptides (Cu chelation risk) | Epitalon (metal ion interference possible) | Copper tripeptide; avoid extended co-storage with metal-chelating compounds |
| CJC-1295 (with DAC) | Ipamorelin | BPC-157 (different dosing schedules) | Semaglutide, Tirzepatide (incompatible logistics) | Most commonly co-administered with Ipamorelin; compatible pH profiles |
| Ipamorelin | CJC-1295, BPC-157, TB-500 | GHRP-6 (redundant receptor; do not combine) | Semaglutide (opposing metabolic effects) | Short-acting GHRP; compatible with most neutral-pH peptides |
| Tesamorelin | Ipamorelin (short-term) | CJC-1295 DAC (possible receptor saturation) | IGF-1 LR3 (feedback redundancy; complex co-admin) | 44-AA peptide; reconstitute separately; sensitive to agitation |
| IGF-1 LR3 | BPC-157 (separate injections preferred) | TB-500 | Disulfide-containing peptides in same vial | Contains 3 disulfide bonds; avoid reducing agents; keep separate from other Cys-containing peptides |
| Selank | Semax | BPC-157 | GH axis peptides (no rationale for co-admin) | Heptapeptide; stable in saline/BAC water; intranasal route preferred |
| Semax | Selank | DSIP | Metabolic peptides (GLP-1 class) | ACTH 4–10 analogue; intranasal or SC; compatible pH with Selank |
| DSIP | Epitalon | Semax, Selank | GH axis peptides | Nonapeptide; primarily studied IV; moderate stability in BAC water |
| Epitalon | DSIP | BPC-157 | GHK-Cu (metal chelation concern) | Tetrapeptide (Ala-Glu-Asp-Gly); compatible with slightly acidic or neutral solutions |
| Melanotan II | PT-141 (same receptor class, but typically not combined) | Selank, Semax | BPC-157, TB-500, IGF-1 LR3, GH axis peptides | Requires initial reconstitution in 0.6% acetic acid; very acidic; avoid mixing with pH-sensitive peptides |
| PT-141 | Melanotan II (same class) | Selank | BPC-157, GH axis peptides | Cyclic heptapeptide; acetic acid reconstitution preferred; keep separate from repair/GH peptides |
| Semaglutide | Tirzepatide (pharmacologically redundant — do not combine) | MOTS-c | All GH axis peptides; BPC-157; repair peptides | Long half-life weekly SC; no benefit to mixing; incompatible scheduling with short-acting peptides |
| Tirzepatide | None (administered alone) | MOTS-c | Semaglutide; all GH axis; BPC-157 | Dual GIP/GLP-1 agonist; weekly dosing; incompatible scheduling with all short-acting peptides |
| Retatrutide | None (administered alone) | MOTS-c | Semaglutide, Tirzepatide, all GH axis | Triple agonist; weekly dosing; administer alone; separate from all other peptides |
| MOTS-c | BPC-157, TB-500 | Ipamorelin, CJC-1295 | Melanotan II, PT-141, GLP-1 class | Mitochondrial-derived peptide; stable in BAC water; compatible with repair peptides |
pH Range Reference by Compound
Understanding the approximate optimal pH for each compound helps predict compatibility when co-reconstituting.
| Compound | Optimal pH Range | Reconstitution Solvent | isoelectric Point (pI) Estimate |
|---|---|---|---|
| BPC-157 | 4.5–6.0 | BAC water or sterile water | ~4.7 |
| TB-500 | 5.0–7.0 | BAC water or sterile water | ~5.0 |
| GHK-Cu | 5.0–7.5 | BAC water or sterile water | ~7.0 (tripeptide with His) |
| CJC-1295 | 5.5–7.5 | BAC water | ~5.8 |
| Ipamorelin | 5.0–7.0 | BAC water or sterile water | ~6.0 |
| Tesamorelin | 6.0–7.5 | BAC water (gentle reconstitution) | ~6.2 |
| IGF-1 LR3 | 6.0–8.0 | BAC water or acetic acid (0.1%) | ~8.5 |
| Selank | 5.5–7.0 | Sterile saline or BAC water | ~6.5 |
| Semax | 5.5–7.0 | Sterile saline or BAC water | ~6.8 |
| DSIP | 5.0–7.0 | BAC water or sterile water | ~4.2 |
| Epitalon | 5.0–7.5 | BAC water or sterile water | ~3.9 |
| Melanotan II | 4.0–5.5 | 0.6% acetic acid (initial), then BAC water | ~7.5 |
| PT-141 | 4.0–5.5 | 0.6% acetic acid (initial), then BAC water | ~7.2 |
| Semaglutide | 6.5–8.0 | BAC water | ~5.8 |
| Tirzepatide | 6.5–8.0 | BAC water | ~6.1 |
| Retatrutide | 6.5–8.0 | BAC water | ~6.3 |
| MOTS-c | 5.5–7.0 | BAC water or sterile water | ~6.0 |
Common Research Stacks
The following combinations appear frequently in published preclinical literature and reported research protocols. All are administered via separate injections unless otherwise noted — co-reconstitution is noted where it is commonly practiced.
| Stack Name | Compounds | Rationale | Timing | Co-Reconstitution |
|---|---|---|---|---|
| GH Pulse Stack | CJC-1295 (no DAC) + Ipamorelin | GHRH analog + GHRP act synergistically on GH release; combined effect significantly exceeds either alone. CJC provides GHRH signal; Ipamorelin provides ghrelin-receptor pulse without cortisol elevation. | Co-administered before sleep or fasting window in rodent models | Yes — compatible pH profiles; frequently co-reconstituted in BAC water |
| Tissue Repair Stack | BPC-157 + TB-500 | BPC-157 promotes angiogenesis and local tissue repair via NO/VEGF pathways; TB-500 (Thymosin β4 fragment) promotes actin polymerization, cell migration, and anti-inflammation. Complementary mechanisms with extensive rodent co-administration literature. | Separate or co-injected; both are typically BID in rodent models | Yes — compatible; both stable in BAC water pH ~5–6 |
| Longevity/Epigenetic Stack | Epitalon + DSIP | Epitalon (pineal peptide) studied for telomere elongation and melatonin normalization; DSIP modulates delta-wave sleep and has cytoprotective properties. Often combined in Russian longevity research protocols. | Evening dosing in rodent models; separate injections preferred | Possible — compatible pH; verify stability before combining |
| Metabolic + Mitochondrial Stack | Semaglutide + MOTS-c | GLP-1 receptor agonism for insulin sensitivity and appetite; MOTS-c activates AMPK and mitochondrial biogenesis. Potentially additive metabolic effects through different pathways. Research is early-stage for this combination. | Separate injections; Semaglutide weekly, MOTS-c more frequent | No — administer separately due to different dosing schedules |
| Cognition Stack | Selank + Semax | Selank (anxiolytic/nootropic tuftsin analog) combined with Semax (ACTH analog with BDNF upregulation); complementary CNS mechanisms. Co-administration reported in Russian clinical research. | Intranasal; often dosed 2–3x daily in research protocols | Possible — similar pH profiles; prefer separate vials for dosing flexibility |
| Skin/Wound Healing Stack | BPC-157 + GHK-Cu | BPC-157 systemic and local tissue repair; GHK-Cu promotes collagen synthesis, wound healing, and antioxidant gene expression. Frequently combined in dermatological and wound-healing research contexts. | SC or topical GHK-Cu; SC BPC-157; separate or co-administration reported | Possible — compatible pH; monitor for Cu chelation effects at high concentration |
Incompatible Combinations
The following combinations should be avoided when co-reconstituting or co-injecting, based on physicochemical incompatibility, opposing mechanisms, or scheduling conflicts that make co-administration scientifically unsound.
| Combination | Reason to Avoid | Category |
|---|---|---|
| Melanotan II + BPC-157 | MT-II requires acetic acid reconstitution (pH ~3.5–4.0); BPC-157 is stable at pH 4.5–6.0 but may degrade in strongly acidic conditions. Significant pH mismatch; aggregation risk. | pH mismatch |
| IGF-1 LR3 + Melanotan II | IGF-1 LR3 contains disulfide bonds sensitive to acidic/reducing environments; MT-II's acetic acid reconstitution environment poses degradation risk. | Chemical stability |
| Semaglutide + Any GH Axis Peptide | GLP-1 agonism reduces GH secretion through somatostatin stimulation; combining with GH secretagogues (Ipamorelin, CJC-1295) is pharmacologically contradictory and scheduling-incompatible (weekly vs. daily). | Opposing mechanisms + scheduling |
| Tirzepatide + Semaglutide | Both act on GLP-1 receptors; Tirzepatide additionally targets GIP-R. Combining creates GLP-1R oversaturation with no additive benefit and elevated adverse effect risk. | Pharmacological redundancy |
| GHK-Cu + Epitalon (in same vial) | GHK-Cu binds copper; Epitalon is an anionic tetrapeptide. Metal ion complexation may alter both peptides' stability and activity profile. | Metal chelation |
| GHRP-6 + Ipamorelin (same vial) | Both are GHRPs acting on GHSR-1a. No additive GH release observed when combined; GHRP-6 increases cortisol and prolactin while Ipamorelin does not — combining adds side-effect risk without benefit. | Pharmacological redundancy + side-effect risk |
| Retatrutide + Any Other Metabolic Peptide | Triple agonist (GLP-1R/GIP-R/GCGR) already provides maximal incretin coverage; adding Semaglutide or Tirzepatide creates receptor redundancy and complex adverse effect profiles. | Pharmacological redundancy |
Solvent Compatibility
The choice of reconstitution solvent affects not only individual peptide stability but also compatibility when mixing. The table below summarizes which solvents are appropriate for which compound classes.
| Solvent | pH | Suitable For | Avoid With | Notes |
|---|---|---|---|---|
| Bacteriostatic Water (BAC, 0.9% benzyl alcohol) | ~4.5–5.5 | Most research peptides: BPC-157, TB-500, GHK-Cu, CJC-1295, Ipamorelin, Tesamorelin, Selank, Semax, DSIP, Epitalon, MOTS-c, Semaglutide, Tirzepatide, Retatrutide | Compounds requiring strict neutral pH (some IGF-1 formulations) | Preferred solvent for multi-dose vials due to bacteriostatic preservation; slight acidity (~5.0) stabilizes most peptide bonds |
| Sterile Water for Injection (SWFI) | ~5.0–7.0 | Any peptide suitable for single-use reconstitution; GHK-Cu, BPC-157, Selank, Semax | Multi-dose vials (no preservative — 24-hour use only); long-term storage | Single-use only; reconstituted solution must be used within 24 hours; no benzyl alcohol for sensitive applications |
| 0.6% Acetic Acid | ~3.0–4.0 | Melanotan II, PT-141, some poorly soluble peptides (initial dissolution step only) | BPC-157, TB-500, IGF-1 LR3, Tesamorelin, GLP-1 analogs (degradation risk) | Used for initial dissolution of hydrophobic/poorly soluble peptides; should be diluted to target concentration with BAC water after dissolution |
| DMSO (dimethyl sulfoxide) | ~7.0 | Highly hydrophobic compounds; topical formulations; some research applications | All injectable formulations (not suitable for SC/IV/IM injection); peptides with disulfide bonds (reducing risk) | Not appropriate for injectable research peptides; used in topical peptide research and cell culture applications only |
| Phosphate-Buffered Saline (PBS) | ~7.4 | In vitro assays; cell culture; some IV research applications; peptides requiring physiological pH (IGF-1 LR3) | Multi-dose storage (no preservative); compounds optimal at acidic pH (BPC-157, Melanotan II) | Physiological pH; useful for cell-based assays; not suitable for multi-dose injectable storage without preservative |
Acetic acid reconstitution protocol: For Melanotan II and PT-141, add a small volume (100–200 µL) of 0.6% acetic acid to achieve initial dissolution, swirl gently, then add the remaining volume as BAC water to reach your target concentration. This avoids the final product being at pH 3–4. Do not mix acetic acid-reconstituted compounds with pH-sensitive peptides.
Mixing Protocol
Why You Always Draw Smallest Volume First
When drawing multiple peptides from different vials into the same syringe, the universal rule is to draw the smallest volume first, then the larger volume. The rationale:
- If you accidentally inject too much of the first compound into the second vial (via back-contamination through the needle), you want the smaller volume to contaminate the larger vial — minimizing the proportion of contamination
- Drawing smaller volumes first ensures better dosing accuracy for the more precisely dosed compound
- If using different concentrations, draw the more concentrated solution first to minimize dead-volume loss of the higher-value compound
Step-by-Step Mixing Protocol
- Verify compatibility using the tables above before attempting to combine any compounds
- Confirm both compounds are fully reconstituted in their respective vials and visually clear (no particulates, no cloudiness)
- Use a new sterile syringe and needle — do not reuse needles between vials
- Draw smallest volume first: insert needle into the first vial (smallest dose), draw the calculated volume, then withdraw needle
- Draw second compound: insert into the second vial, draw the required volume into the same syringe
- Inspect the combined solution: look for cloudiness, precipitation, or color change — any of these indicates incompatibility; discard and do not inject
- Administer promptly: mixed solutions should be administered within a few minutes; do not store a pre-mixed syringe
Never mix directly in a vial. Adding one reconstituted peptide to another peptide's vial risks contaminating the entire stock with an incompatible compound. Always combine in the syringe immediately before administration.
References
- Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Curr Med Chem. 2012;19(1):126–132. PMID: 22300081. PubMed →
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421–429. PMID: 16099219. PubMed →
- Pickart L, Margolina A. "Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data." Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. PubMed →
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552–561. PMID: 9849822. PubMed →
- Lau J, Bloch P, Schäffer L, et al. "Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide." J Med Chem. 2015;58(18):7370–7380. PMID: 26308095. PubMed →
- Kim SJ, Mehta HH, Wan J, et al. "Mitochondrial peptides modulate mitochondrial function during cellular senescence." Aging (Albany NY). 2018;10(6):1239–1256. PMID: 29906834. PubMed →
- Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. "Melanocortin receptor agonists, penile erection, and sexual motivation." Int J Impot Res. 2000;12 Suppl 4:S74–79. PMID: 10845756. PubMed →
Related Resources
Research Use Only. All compatibility assessments on this page are derived from physicochemical principles and published literature for laboratory research reference purposes only. Mixing peptides for human administration is outside the intended use of these compounds. Alpha Tides compounds are intended exclusively for qualified laboratory researchers. Not for human consumption.